Comparing Exicure (NASDAQ:XCUR) and Zealand Pharma A/S (OTCMKTS:ZLDPF)

Zealand Pharma A/S (OTCMKTS:ZLDPF) and Exicure (NASDAQ:XCUR) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations and dividends.

Valuation and Earnings

This table compares Zealand Pharma A/S and Exicure”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zealand Pharma A/S	$1.40 billion	2.42	$977.29 million	$6.03	7.84
Exicure	$500,000.00	16.90	-$4.95 million	($1.32)	-0.98

Zealand Pharma A/S has higher revenue and earnings than Exicure. Exicure is trading at a lower price-to-earnings ratio than Zealand Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

42.8% of Exicure shares are held by institutional investors. 52.8% of Exicure shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings for Zealand Pharma A/S and Exicure, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zealand Pharma A/S	1	7	1	1	2.20
Exicure	1	0	0	0	1.00

Profitability

This table compares Zealand Pharma A/S and Exicure’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zealand Pharma A/S	58.86%	18.53%	17.14%
Exicure	N/A	-237.91%	-61.98%

Risk & Volatility

Zealand Pharma A/S has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500. Comparatively, Exicure has a beta of 3.63, suggesting that its stock price is 263% more volatile than the S&P 500.

Summary

Zealand Pharma A/S beats Exicure on 10 of the 14 factors compared between the two stocks.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.

About Exicure

Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.